|Videos|September 17, 2017

Hospital Epidemiologist: An Undefined Role?

Author(s)Contagion&reg Editorial Staff

Silvia Munoz-Price, MD, PhD, explains how the undefined role of a hospital epidemiologist can be problematic.

Silvia Munoz-Price, MD, PhD, associate professor of clinical medicine at the Institute for Health and Society, Medical College of Wisconsin, and enterprise epidemiologist for Froedtert & the Medical College of Wisconsin, explains how the undefined role of a hospital epidemiologist can be problematic. One reason that Dr. Munoz-Price points out has to do with bundles. She notes that although bundles have been very effective in reducing countless infections, they essentially reduce the field of hospital epidemiology to just bundle implementation.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 23rd, 2026

Household Contacts Drive Most Hepatitis B Exposures in Young Children

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

October 27th, 2026

ID Week Highlights Part 1

In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.

October 27th, 2026

IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections

David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.

October 26th, 2026

Novel RSV Therapy: Addressing a Clinical Need

Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.

October 26th, 2026

Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial

Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.

October 25th, 2026

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.

Alisse Hannaford, MD (Image Credit: Mass General)

October 24th, 2026

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.

October 24th, 2026

Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy

Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.